ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

  • Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting

    Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis

    Javier Narváez1, Milagros Ricse2, Juan José Alegre3, Gloria Albert Espi3, Carmen Gomez Vaquero4, Helena Borrell Paños2, Eulalia Armengol2, Joan Miquel Nolla2, Susana Herrera5 and Maria Molina6, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 4Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, 5Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, 6Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
  • Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting

    B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens

    Geraldine Cambridge1, Lauren J. Lahey2, Maria J. Leandro1, William H. Robinson3 and Jeremy Sokolove4, 1Rheumatology, University College London, London, United Kingdom, 2Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 3VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA

    Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
  • Abstract Number: 1668 • 2015 ACR/ARHP Annual Meeting

    Patterns of Relapse in the Rheumatoid Arthritis Cohort Treated with Rituximab at University College London

    Elena Becerra, Geraldine Cambridge, Inmaculada de la Torre and Maria J. Leandro, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Patterns of relapse in the Rheumatoid Arthritis cohort treated with Rituximab at University College LondonBackground/Purpose: Two patterns of relapse were defined in the first studies…
  • Abstract Number: 1942 • 2015 ACR/ARHP Annual Meeting

    B Cell Depletion By Rituximab in Lymphocyte Subpopulations from Peripheral Blood in Patients with Rheumatoid Arthritis

    Leticia Merino-Meléndez1, Jorge López-López2, Irene Llorente1, Santos Castañeda3, Federico Herrera2, Teresa Velasco4, Lorena Vega5, Francisco Rodriguez5, Jose María Alvaro-Gracia3, Rosario Garcia-Vicuña6, Cecilia Muñoz-Calleja2 and Isidoro Gonzalez-Alvaro7, 1Rheumatology, H.U. La Princesa, Madrid, Spain, 2Immunology, Hospital Universitario de La Princesa, Madrid, Spain, 3Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 4Rheumatology, H.U La Princesa, Madrid, Spain, 5H.U. La Princesa, Madrid, Spain, 6Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 7Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that leads to inflammation of the joints and other tissues. Rituximab (Rtx) is a therapeutic monoclonal antibody…
  • Abstract Number: 2058 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Rituximab Biosimilar Candidate (CT-P10) and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase I Randomized Controlled Trial over 72 Weeks

    Dae-Hyun Yoo1, Won Park2, Chang-Hee Suh3, Seung-Cheol Shim4, Slawomir Jeka5, Fidencio Cons Molina6, Pawel Hrycaj7, Wolfgang Spieler8, Piotr Wiland9, Jan Brzezicki10, Eun Young Lee11, Francisco G. Medina-Rodriguez12, Pavel Shesternya13, Sebastiao Radominski14, Marina Stanislav15, Volodymyr Kovalenko16, Donghyuk Sheen17, Leysan Myasoutova18, Mie Jin Lim19, Jung-Yoon Choe20, Taek S. Kwon21 and Sang Joon Lee21, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 3Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, 4Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 5University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, 6Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 7Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 8Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 9Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 10Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, 11Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 12Rheumatology, LaSalle University, Mexico City, Mexico, 13Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, 14CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, 15Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, 16Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, 17Rheumatology, Eulji University Hospital, Daejeon, South Korea, 18City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, 19Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, 20Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, 21CELLTRION, Inc., Incheon, South Korea

    Background/Purpose: CT-P10 is a biosimilar candidate of innovator rituximab (RTX). PK profile and clinical data up to week 24 has been reported at ACR 20131.…
  • Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting

    Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups

    Dae-Hyun Yoo1, Won Park2, Slawomir Jeka3, Fidencio Cons Molina4, Pawel Hrycaj5, Piotr Wiland6, Wolfgang Spieler7, Eun Young Lee8, Francisco G. Medina-Rodriguez9, Pavel Shesternya10, Sebastiao Radominski11, Dong Hyuk Sheen12, Mie Jin Lim13, Jung-Yoon Choe14, Leysan Myasoutova15, Taek Kwon16, Sang Joon Lee16, Seung-Cheol Shim17 and Chang-Hee Suh18, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 3University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, 4Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 5Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 6Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 7Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 8Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 9Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, 10Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, 11CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, 12Rheumatology, Eulji University Hospital, DaeJeon, South Korea, 13Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, 14Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, 15City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, 16CELLTRION, Inc., Incheon, South Korea, 17Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 18Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea

    Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
  • Abstract Number: 1502 • 2014 ACR/ARHP Annual Meeting

    A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis

    Jean-Claude P. Becker1, Donghua Yin2, Lisa Ann Melia3, Ruifeng Li4, Barry Gumbiner5, Dolca Thomas6, George Spencer-Green7 and Xu Meng2, 1Pfizer Biosimilars Research and Development/Medical Affairs., Pfizer Inc., New York, NY, 2Clinical Pharmacology/Pharmacometrics, Pfizer Inc., San Diego, CA, 3Biotechnology Clinical Development, Pfizer Inc., San Diego, CA, 4Biostatistics, Pfizer Inc., Cambridge, MA, 5Worldwide Research and Development, Pfizer Inc., San Diego, CA, 6Biosimilars Research and Development Unit, Pfizer Inc., New York, NY, 7Worldwide Research and Development, Pfizer Inc., Cambridge, MA

    Background/Purpose: PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar physicochemical and in vitro functional properties. This…
  • Abstract Number: 1419 • 2014 ACR/ARHP Annual Meeting

    Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience

    Sandra Chartrand1,2, Jeffery J. Swigris3, Lina Peykova2 and Aryeh Fischer4, 1Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, 2Rheumatology, National Jewish Health, Denver, CO, 3Autoimmune Lung Center, National Jewish Health, Denver, CO, 4Rheumatology / ILD Program, National Jewish Health, Denver, CO

    Background/Purpose: Small series have suggested that rituximab (RTX) may be effective as rescue-therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We sought to describe…
  • Abstract Number: 991 • 2014 ACR/ARHP Annual Meeting

    The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis

    Cecile Gamonet1, Marina Deschamps2, Sandrine Marion3, Philippe Saas4, Gilles Chioccha3, Christophe Ferrand4 and Eric Toussirot5,6, 1INSERM UMR1098, Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 2INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, 3Chronic Inflammation and Immune System Labex Inflamex, Université Versailles Saint Quentin, Montigny le Bretonneux, France, 4Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, 5Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, 6Rheumatology, University hospital, Besançon, France

    Background/Purpose: the identification of predictive factors for the response, or alternatively factors for resistance to biological agents is a relevant goal in the management of…
  • Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting

    Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study

    Kenneth G. Saag1, Kevin L. Winthrop2, Daniel E. Furst3, Kimberly Alexander4, Angelika Jahreis5, Carol Chung6 and Kurt Oelke7, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 3University of California at Los Angeles, Los Angeles, CA, 4Epidemiology, Genentech, Inc., South San Francisco, CA, 5Genentech, South San Francisco, CA, 6Genentech, Inc, South San Francisco, CA, 7Rheumatic Disease Center, Glendale, WI

    Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…
  • Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting

    Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial

    Jérémie Sellam1, Houria Chavez2, Stéphanie Rouanet3, Nathalie Vernet3, Bineta Ly4, Sandrine Marion-Thore5, Bernard Combe6, Jean Sibilia7, Jacques Tebib8, Gilles Chiocchia9, Maxime Dougados10, Yassine Taoufik2 and Xavier Mariette11, 1AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, 2Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, 3Biostatistics, Roche France, Boulogne-Billancourt, France, 4INSERM U1012, Universite Paris-Sud, Kremlin Bicetre, France, 5INSERM U1016, Université Versailles Saint-Quentin, Montigny le Bretonneux, France, 6Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 8Rheumatology, University Hospital Lyon, Lyon, France, 9Université Versailles-Saint Quentin, Montigny le Bretonneux, France, 10INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 11rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France

    Background/Purpose .  The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…
  • Abstract Number: 2524 • 2014 ACR/ARHP Annual Meeting

    Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration

    Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny Nasonov3, Galina Lukina3, Merete Lund Hetland4, Ellen Hauge5, Karel Pavelka6, Cem Gabay7, Dan Nordström8, Helena Canhão9, Matija Tomsic10, Piet van Riel11, Juan J. Gomez-Reino12, Ioan Ancuta13, Tore K. Kvien14, Ronald F. van Vollenhoven15 and Saedis Saevarsdottir16, 1Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 10Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, 11Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 12Rheumatology, Hospital Clinico Universitario, Santiago, Spain, 13“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 14Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 15Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 16Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Smoking has been identified as an important negative predictor of response to antirheumatic therapy. The aim of this study was to assess whether smoking…
  • Abstract Number: 2497 • 2014 ACR/ARHP Annual Meeting

    Correlation Between Time to  Switch  and Clinical Response Amplitude to  Rituximab in Second  Line  Treatment  in Rheumatoid Arthritis  Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study

    Ioan Ancuta1, Ruxandra Ionescu2, Catalin Codreanu3, Andra Balanescu2, Elena Rezus4, Maria Suta5, Paulina Ciurea6, Mihaela Milicescu7, Dan Nemes8, Codrina Ancuta9, Mihai Bojinca10, Magda Parvu11 and Horatiu Popoviciu12, 1“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 2Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 35 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 4Rheumatology, Recovering Clinical Hospital, Iasi, Romania, 5317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, 6Clinical County Hospital,Craiova, Craiova, Romania, 7Rheumatology, "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania, 8Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 9G.T.Popa Center for Biomedical Research, Iasi, Romania, 10Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 11Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, 12Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania

    Background/Purpose: In recent years we assist to an increasing interest to get more clinical data to improve the control of disease course in rheumatoid arthritis…
  • Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting

    Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies

    M. Victoria Hernández1, Andrea Cuervo1, Sonia Cabrera1, Jose Inciarte-Mundo1, Julio Ramirez1, Virginia Ruiz-Esquide1, Juan D. Cañete2 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic, Barcelona, Spain

    Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…
  • Abstract Number: 2412 • 2014 ACR/ARHP Annual Meeting

    Regime of Use of Rituximab in Patients with Rheumatoid Arthritis in Daily Clinical Practice

    Leticia Merino-Meléndez1, Irene Llorente2, Santos Castañeda3, Teresa Velasco2, Luis Sala-Icardo4, Rosario Garcia-Vicuña4, Alberto Garcia-Vadillo5, Juan P. López-Bote4, Jorge López-López6, Federico Herrera6, Cecilia Muñoz-Calleja6, JM Álvaro-Gracia2 and Isidoro González-Alvaro4, 1Rheumatology Department, Hospital Universitario de La Princesa, Madrid, Spain, 2Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 3Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, 4Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 5Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, 6Immunology, Hospital Universitario de La Princesa, Madrid, Spain

    Background/Purpose: The recommended therapeutic regime for Rituximab (RTX) in Rheumatoid Arthritis (RA), according to prescribing information, includes two 1000-milligram infusions given two weeks apart, every…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology